FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000521013> ?p ?o ?g. }

• W3000521013 endingPage "500" @default.
• W3000521013 startingPage "495" @default.
• W3000521013 abstract "Background Systemic second- and third-line therapies for malignant pleural mesothelioma (MPM) result in a median progression-free survival (mPFS) of Patients and methods Pts with progressing MPM treated with first-line platinum-pemetrexed chemotherapy with or without immunotherapy received lurbinectedin monotherapy. Treatment was given intravenously at 3.2 mg/m2 dose every 3 weeks until progression or unacceptable toxicity. Using Simon's two-stage design, the primary endpoint, progression-free survival (PFS) at 12 weeks (PFS12wks), was met if achieved by ≥21 pts (p0 ≤35% versus p1 ≥55%). Results Forty-two pts from nine centres across Switzerland and Italy were recruited. Histology was epithelioid in 33 cases, sarcomatoid in 5, and biphasic in 4. Overall 10/42 (23.8%) underwent prior immunotherapy and 14/42 (33.3%) had progressed ≤6 months after first-line chemotherapy. At data cut-off PFS12wks was met by 22/42 pts (52.4%; 90% confidence interval (CI): 38.7% to 63.5%; P = 0.015) with an mPFS of 4.1 months and mOS of 11.1 months. The best response was complete and partial remission observed in one patient each and stable disease in 20 pts. The duration of disease control was 6.6 months (95% CI: 5.2–7.4). No significant difference in PFS12wks, mPFS, and mOS was recorded in epithelioid versus non-epithelioid cases and pts with prior immunotherapy versus those without. Similar mPFS but shorter mOS were observed among pts who progressed within ≤6 months after first-line chemotherapy. Lurbinectedin-related grade 3–4 toxicity was seen in 21 pts, mostly being neutropenia (23.8%) and fatigue (16.7%). Conclusions The primary efficacy endpoint was reached with acceptable toxicity. Lurbinectedin showed promising activity regardless of histology, prior immunotherapy, or outcome on prior treatment. ClinicalTrials.gov Identifier NCT03213301" @default.
• W3000521013 created "2020-01-23" @default.
• W3000521013 creator A5008022418 @default.
• W3000521013 creator A5011868198 @default.
• W3000521013 creator A5025804381 @default.
• W3000521013 creator A5030461544 @default.
• W3000521013 creator A5038016963 @default.
• W3000521013 creator A5038556220 @default.
• W3000521013 creator A5042504734 @default.
• W3000521013 creator A5044032162 @default.
• W3000521013 creator A5051919018 @default.
• W3000521013 creator A5062532607 @default.
• W3000521013 creator A5066360417 @default.
• W3000521013 creator A5071311341 @default.
• W3000521013 creator A5074349466 @default.
• W3000521013 creator A5077047695 @default.
• W3000521013 creator A5078606948 @default.
• W3000521013 creator A5080098952 @default.
• W3000521013 creator A5081312940 @default.
• W3000521013 creator A5085017956 @default.
• W3000521013 date "2020-04-01" @default.
• W3000521013 modified "2023-09-26" @default.
• W3000521013 title "Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)" @default.
• W3000521013 cites W1239915614 @default.
• W3000521013 cites W1555559948 @default.
• W3000521013 cites W1893244802 @default.
• W3000521013 cites W2051530367 @default.
• W3000521013 cites W2082476295 @default.
• W3000521013 cites W2097268076 @default.
• W3000521013 cites W2100576484 @default.
• W3000521013 cites W2102236439 @default.
• W3000521013 cites W2117114306 @default.
• W3000521013 cites W2124844765 @default.
• W3000521013 cites W2134594118 @default.
• W3000521013 cites W2165750757 @default.
• W3000521013 cites W2169012257 @default.
• W3000521013 cites W2285815371 @default.
• W3000521013 cites W2329484952 @default.
• W3000521013 cites W2725758645 @default.
• W3000521013 cites W2734373861 @default.
• W3000521013 cites W2801312821 @default.
• W3000521013 cites W2811278093 @default.
• W3000521013 cites W2888754876 @default.
• W3000521013 cites W2896595201 @default.
• W3000521013 cites W2909198142 @default.
• W3000521013 cites W4211134618 @default.
• W3000521013 doi "https://doi.org/10.1016/j.annonc.2019.12.009" @default.
• W3000521013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32085891" @default.
• W3000521013 hasPublicationYear "2020" @default.
• W3000521013 type Work @default.
• W3000521013 sameAs 3000521013 @default.
• W3000521013 citedByCount "21" @default.
• W3000521013 countsByYear W30005210132020 @default.
• W3000521013 countsByYear W30005210132021 @default.
• W3000521013 countsByYear W30005210132022 @default.
• W3000521013 countsByYear W30005210132023 @default.
• W3000521013 crossrefType "journal-article" @default.
• W3000521013 hasAuthorship W3000521013A5008022418 @default.
• W3000521013 hasAuthorship W3000521013A5011868198 @default.
• W3000521013 hasAuthorship W3000521013A5025804381 @default.
• W3000521013 hasAuthorship W3000521013A5030461544 @default.
• W3000521013 hasAuthorship W3000521013A5038016963 @default.
• W3000521013 hasAuthorship W3000521013A5038556220 @default.
• W3000521013 hasAuthorship W3000521013A5042504734 @default.
• W3000521013 hasAuthorship W3000521013A5044032162 @default.
• W3000521013 hasAuthorship W3000521013A5051919018 @default.
• W3000521013 hasAuthorship W3000521013A5062532607 @default.
• W3000521013 hasAuthorship W3000521013A5066360417 @default.
• W3000521013 hasAuthorship W3000521013A5071311341 @default.
• W3000521013 hasAuthorship W3000521013A5074349466 @default.
• W3000521013 hasAuthorship W3000521013A5077047695 @default.
• W3000521013 hasAuthorship W3000521013A5078606948 @default.
• W3000521013 hasAuthorship W3000521013A5080098952 @default.
• W3000521013 hasAuthorship W3000521013A5081312940 @default.
• W3000521013 hasAuthorship W3000521013A5085017956 @default.
• W3000521013 hasBestOaLocation W30005210131 @default.
• W3000521013 hasConcept C126322002 @default.
• W3000521013 hasConcept C142724271 @default.
• W3000521013 hasConcept C143998085 @default.
• W3000521013 hasConcept C2776694085 @default.
• W3000521013 hasConcept C2777407522 @default.
• W3000521013 hasConcept C2909905744 @default.
• W3000521013 hasConcept C71924100 @default.
• W3000521013 hasConceptScore W3000521013C126322002 @default.
• W3000521013 hasConceptScore W3000521013C142724271 @default.
• W3000521013 hasConceptScore W3000521013C143998085 @default.
• W3000521013 hasConceptScore W3000521013C2776694085 @default.
• W3000521013 hasConceptScore W3000521013C2777407522 @default.
• W3000521013 hasConceptScore W3000521013C2909905744 @default.
• W3000521013 hasConceptScore W3000521013C71924100 @default.
• W3000521013 hasFunder F4320327373 @default.
• W3000521013 hasFunder F4320327811 @default.
• W3000521013 hasFunder F4320335238 @default.
• W3000521013 hasIssue "4" @default.
• W3000521013 hasLocation W30005210131 @default.
• W3000521013 hasOpenAccess W3000521013 @default.
• W3000521013 hasPrimaryLocation W30005210131 @default.
• W3000521013 hasRelatedWork W1800520966 @default.

• next